Quantcast

Latest Tegaserod Stories

b0957c64f088eedca4cb437867702267
2010-07-15 06:05:00

A panel of U.S. Food and Drug Administration advisers voted Wednesday to allow GlaxoSmithKline's diabetes drug Avandia to remain on the market, but with new restrictions due to the risky cardiovascular side effects of the controversial pill. The panel of experts voted 20-12 to retain availability of Avandia to diabetics, although 10 panelists called for limiting who can receive and prescribe the once-blockbuster medication. British drugmaker Glaxo has been hit with thousands of lawsuits from...

2009-09-14 11:01:00

CAMBRIDGE, Mass., Sept. 14 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced that Thomas McCourt has joined the Company as chief commercial officer and senior vice president of marketing and sales. Mr. McCourt will be responsible for overall commercial strategy and execution and will lead Ironwood's growing marketing and sales team. (Logo: http://www.newscom.com/cgi-bin/prnh/20081006/NEM080ALOGO ) Mr. McCourt comes to Ironwood from Amgen, where he led the U.S. brand team for...

2009-08-05 09:00:17

 The adult lower digestive tract can be stimulated to add neurons to the intestinal system, according to new mouse research in the August 5 issue of The Journal of Neuroscience. The study shows that drugs similar to the neurotransmitter serotonin increase the production of new neurons in the gut. This is the first research to confirm that an adult intestine can generate neurons in the enteric nervous system, the network of neurons in the gut's wall that controls the gastrointestinal...

2008-10-21 09:00:12

Sucampo Pharma Europe, Ltd., a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), today announced the results from three open-labeled, long-term (6 and 12 months) clinical trials of lubiprostone (AMITIZA(R)). These trials were conducted between November 2001 and January 2005 and the results were previously reported in the United States. These data demonstrate that lubiprostone provided significant improvements in subjective assessments of symptoms and was well tolerated...

2008-09-18 18:00:19

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced results of its phase 2b dose-ranging study of AMITIZA(R) (lubiprostone) in patients with Chronic Idiopathic Constipation (CIC), conducted in Japan. The study demonstrated a statistically significant increase in mean change in spontaneous bowel movements (SBM) from baseline after one week on treatment (p less than 0.0001), the study's primary endpoint, for patients taking AMITIZA 24 micrograms twice daily versus placebo. AMITIZA...

2008-08-18 12:00:14

By PETER GOTT Dear Dr. Gott: I took Zelnorm over a year ago, until my doctor said the Food and Drug Administration had taken it off the market and it was no longer available. Since I was suffering from chronic constipation, it was very helpful in regulating my system. I've had nothing but problems now that I'm not using it. I've tried a number of prescription drugs, over-the-counter stool softeners and just about everything I can find. Nothing works like Zelnorm did. I hope there will...

2008-07-21 12:00:20

Callisto Pharmaceuticals, Inc. (Pink Sheets: CLSP; FWB: CA4), announced today that its Synergy Pharmaceuticals, Inc. closed a $3.0 million private placement. The proceeds of the private placement will be used to fund the development of SP-304, its guanylate cyclase C (GC-C) receptor agonist, for chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C). Simultaneously with the closing of the placement, Callisto and certain recipients of Synergy restricted stock...

2008-06-18 12:00:11

Research and Markets (http://www.researchandmarkets.com/research/e40571/gastrointestinal_d) has announced the addition of the "Gastrointestinal Drug Discoveries: What the Future Holds" report to their offering. This new strategic report from Espicom provides a comprehensive review of current and future treatments for major gastrointestinal therapy areas: inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and gastro-oesophageal reflux disease (GORD). Inflammatory Bowel...

2008-05-28 12:00:08

Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America have announced that Amitiza 8mcg capsules are now available by prescription in pharmacies across the US for the treatment of irritable bowel syndrome with constipation in women 18 years and older. Amitiza has a mechanism of action that works locally in the intestine to increase fluid secretion, resulting in increased passage of stool and alleviating symptoms associated with chronic idiopathic constipation. Amitiza was...

2005-10-31 12:53:15

American College of Gastroenterology 70th Annual Scientific Meeting HONOLULU, October 31, 2005 -- A new study shows that treating Irritable Bowel Syndrome (IBS) with constipation may have a significant impact on absenteeism from work, as well as improving presenteeism "“ defined as coming to work but being less productive. Canadian researchers from The University of Alberta and Novartis Pharmaceuticals Canada presented findings of a study of tegaserod in patients with IBS characterized...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related